Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
PC-002L
- Development stage
- Preclinical
- Lead developer
- Cothera Bioscience
- Modality
- Small Molecules
01
Overview
PC-002L is a next-generation small molecule formulation of PC-002 (sepantronium bromide) being developed by Cothera Bioscience. It functions as an inhibitor of the deubiquitinase (DUB) enzyme USP7 (Ubiquitin-specific protease 7). By inhibiting USP7, the drug prevents the removal of ubiquitin chains from oncogenic proteins, thereby promoting their proteasomal degradation. This mechanism is particularly relevant in cancers driven by MYC family proteins, such as Small Cell Lung Cancer (SCLC) with N-MYC amplification, where the stabilization of these proteins is critical for tumor cell survival. PC-002L is designed to improve upon the pharmacological and therapeutic properties of the original PC-002 formulation and is currently in preclinical development.
- Other names
- next-generation formulation of PC-002
02
Targets
USP7
Beyond the preview
Go deeper on PC-002L.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on PC-002L.